Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 62

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Drug‐Nutrient Interactions

Chan, Lingtak‐Neander·2013·Journal of Parenteral and Enteral Nutrition

Abstract

Drug‐nutrient interactions are defined as physical, chemical, physiologic, or pathophysiologic relationships between a drug and a nutrient. The causes of most clinically significant drug‐nutrient interactions are usually multifactorial. Failure to identify and properly manage drug‐nutrient interactions can lead to very serious consequences and have a negative impact on patient outcomes. Nevertheless, with thorough review and assessment of the patient's history and treatment regimens and a carefully executed management strategy, adverse events associated with drug‐nutrient interactions can be prevented. Based on the physiologic sequence of events after a drug or a nutrient has entered the body and the mechanism of interactions, drug‐nutrient interactions can be categorized into 4 main types. Each type of interaction can be managed using similar strategies. The existing data that guide the clinical management of most drug‐nutrient interactions are mostly anecdotal experience, uncontrolled observations, and opinions, whereas the science in understanding the mechanism of drug‐nutrient interactions remains limited. The challenge for researchers and clinicians is to increase both basic and higher level clinical research in this field to bridge the gap between the science and practice. The research should aim to establish a better understanding of the function, regulation, and substrate specificity of the nutrient‐related enzymes and transport proteins present in the gastrointestinal tract, as well as assess how the incidence and management of drug‐nutrient interactions can be affected by sex, ethnicity, environmental factors, and genetic polymorphisms. This knowledge can help us develop a true personalized medicine approach in the prevention and management of drug‐nutrient interactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0148607113488799

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 54

  1. 10.1111/j.1365-2125.2010.03722.x · DOI
  2. 10.1097/MPG.0b013e3181eb5ad6 · DOI
  3. Chan L‐N, 2013, Modern Nutrition in Health and Disease, 1442
  4. 10.1038/clpt.2012.159 · DOI
  5. 10.4088/JCP.11096su1c.03 · DOI
  6. MacDonald L, 2009, Food and therapeutic product interactions: a therapeutic perspective, J Pharm Pharm Sci, 12, 367, 10.18433/J30P4C · DOI
  7. 10.1016/j.pharmthera.2012.08.001 · DOI
  8. 10.1159/000331519 · DOI
  9. 10.1007/s10620-011-1589-y · DOI
  10. 10.2337/dc12-0980 · DOI
  11. 10.1007/s11894-010-0141-0 · DOI · Paper page
  12. 10.1038/ajg.2009.45 · DOI
  13. 10.1016/j.amjopharm.2010.02.003 · DOI
  14. 10.1212/WNL.58.9.1348 · DOI · Paper page
  15. Feldkamp J, 2000, Long‐term anticonvulsant therapy leads to low bone mineral density—evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast‐like cells, Exp Clin Endocrinol Diabetes, 108, 37
  16. 10.1111/j.1538-7836.2008.03003.x · DOI
  17. 10.1038/tpj.2011.4 · DOI
  18. Chan L‐N, Modern Nutrition in Health and Disease, 1539
  19. 10.1021/bi700527j · DOI
  20. 10.1111/j.1538-7836.2005.01419.x · DOI · Paper page
  21. U.S. Food and Drug Administration (FDA), 2002, Guidance for Industry: Food‐effect Bioavailability and Fed Equivalence Studies
  22. 10.1097/MPG.0b013e3181eb5ad6 · DOI
  23. 10.1111/j.2042-7158.2012.01505.x · DOI
  24. 10.1007/s00424-003-1192-y · DOI · Paper page
  25. 10.1007/s11095-009-9924-0 · DOI · Paper page
  26. Estudante M, Intestinal drug transporters: an overview, Adv Drug Deliv Rev
  27. 10.1016/j.bcp.2005.09.027 · DOI
  28. 10.1111/j.1476-5381.2011.01438.x · DOI
  29. 10.1152/physiol.00027.2010 · DOI
  30. 10.1111/j.1476-5381.2011.01724.x · DOI · Paper page
  31. 10.1146/annurev-pharmtox-010510-100556 · DOI · Paper page
  32. 10.1023/A:1021918104127 · DOI
  33. 10.1016/j.genhosppsych.2011.12.009 · DOI
  34. 10.1016/j.braindev.2005.11.005 · DOI
  35. Moreno FA, 2005, Carnitine levels in valproic acid–treated psychiatric patients: a cross‐sectional study, J Clin Psychiatry, 66, 555, 10.4088/JCP.v66n0502 · DOI
  36. Okamura M, 2003, Inhibitory effect of zinc on PEPT1‐mediated transport of glycylsarcosine and beta‐lactam antibiotics in human intestinal cell line Caco‐2, Pharm Res, 20, 1389, 10.1023/A:1025797808703 · DOI
  37. 10.2133/dmpk.23.464 · DOI
  38. 10.1002/jps.22627 · DOI
  39. 10.1517/14740338.6.6.695 · DOI
  40. 10.1016/j.jclinepi.2003.08.015 · DOI
  41. Sheen E, Adverse effects of long‐term proton pump inhibitor therapy, Dig Dis Sci, 56, 931, 10.1007/s10620-010-1560-3 · DOI · Paper page
  42. 10.1111/j.1365-2036.2008.03658.x · DOI
  43. 10.1016/j.bone.2008.03.002 · DOI
  44. Moro‐Alvarez MJ, 2009, Bone disease induced by phenytoin therapy: clinical and experimental study, Eur Neurol, 62, 219, 10.1159/000229309 · DOI
  45. 10.1128/AAC.38.9.2101 · DOI
  46. 10.1093/jac/38.5.871 · DOI
  47. Mimoz O, 1998, Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients, Intensive Care Med, 24, 1047, 10.1007/s001340050714 · DOI
  48. 10.1177/014860710002400142 · DOI
  49. 10.1212/WNL.32.5.570 · DOI
  50. 10.1592/phco.28.3.308 · DOI
  51. 10.1016/j.nut.2008.05.015 · DOI
  52. 10.1177/0884533610385701 · DOI
  53. 10.1345/aph.19355 · DOI
  54. Chan L‐N, 2012, To hold (enteral feeding) or not to hold: that is the question; a commentary and tutorial, Pract Gastroenterol, 13

Cited by

Metadata

Authors
Chan, L.
Venue
Journal of Parenteral and Enteral Nutrition
Publisher
Wiley
Published
2013-05-14
Volume
37
Issue
4
Pages
450-459
ISSN
  • 0148-6071
  • 1941-2444
Cited by
62
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.